Literature DB >> 10556673

The assessment of antagonist potency under conditions of transient response kinetics.

A Christopoulos1, A M Parsons, M J Lew, E E El-Fakahany.   

Abstract

The muscarinic acetylcholine receptor antagonists, atropine and pirenzepine, produced an apparent insurmountable antagonism of muscarinic M(1) receptor-mediated intracellular Ca(2+) mobilization in Chinese hamster ovary (CHO) cells when tested against the agonists carbachol or xanomeline. Each antagonist caused a dextral shift of the agonist concentration-response curves with depression of the maximum response that was incomplete (i.e., saturated) and which varied with the pairs of agonist and antagonist. Equilibrium competition binding assays found no deviation from simple, reversible competitive behavior for either antagonist. The relative rates of dissociation of unlabeled atropine and pirenzepine were also assessed in radioligand kinetic studies and it was found that atropine dissociated from the receptor approximately 8-fold slower than pirenzepine. Numerical dynamic simulations suggested that the insurmountability of antagonism observed in the present study was probably a kinetic artifact related to the measurement of transient responses to a non-equilibrated agonist in the presence of a slowly dissociating antagonist. Importantly, the patterns of antagonism observed included a saturable depression of agonist maximal response, a mode of antagonism that is incompatible with the previously described phenomenon of hemi-equilibrium states. Monte Carlo simulations indicated that reasonable, semi-quantitative estimates of antagonist potency could be determined by a minor modification of standard methods, where equieffective agonist concentrations, rather than EC(50) values, are compared in the absence and presence of antagonist. Application of the latter approach to the functional data yielded estimates of antagonist potency that were in excellent agreement with those derived from the equilibrium binding assays, thus indicating that the present method can be useful for quantifying antagonist potency under non-equilibrium conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556673     DOI: 10.1016/s0014-2999(99)00550-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Modelling of alpha1-adrenoceptor-mediated temporal dynamics of inotropic response in rat heart to assess ligand binding and signal transduction parameters.

Authors:  P Sermsappasuk; M Weiss
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

3.  A novel fluorescent histamine H(1) receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands.

Authors:  Rachel H Rose; Stephen J Briddon; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

5.  Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor.

Authors:  Zhi Yuan Kok; Leigh A Stoddart; Sarah J Mistry; Tamara A M Mocking; Henry F Vischer; Rob Leurs; Stephen J Hill; Shailesh N Mistry; Barrie Kellam
Journal:  J Med Chem       Date:  2022-06-03       Impact factor: 8.039

6.  Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.

Authors:  Gregory J Digby; Thomas J Utley; Atin Lamsal; Christian Sevel; Douglas J Sheffler; Evan P Lebois; Thomas M Bridges; Michael R Wood; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2012-09-09       Impact factor: 4.418

7.  Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation.

Authors:  L E Kilpatrick; S J Briddon; S J Hill; N D Holliday
Journal:  Br J Pharmacol       Date:  2010-04-28       Impact factor: 8.739

8.  Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo.

Authors:  Claudia A Soto; Matthew J Shashack; Robert G Fox; Marcy J Bubar; Kenner C Rice; Cheryl S Watson; Kathryn A Cunningham; Scott R Gilbertson; Noelle C Anastasio
Journal:  ACS Chem Neurosci       Date:  2017-11-21       Impact factor: 4.418

9.  Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.

Authors:  Caren L Steinmiller; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

10.  Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.

Authors:  Arhamatoulaye Maïga; Jon Merlin; Elodie Marcon; Céline Rouget; Maud Larregola; Bernard Gilquin; Carole Fruchart-Gaillard; Evelyne Lajeunesse; Charles Marchetti; Alain Lorphelin; Laurent Bellanger; Roger J Summers; Dana S Hutchinson; Bronwyn A Evans; Denis Servent; Nicolas Gilles
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.